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Purpose: This dose-escalation study was performed to determine 
the recommended phase II dose of oral capecitabine to be delivered 
concurrently with thoracic radiation therapy and weekly docetaxel in 
patients with locally advanced esophageal carcinoma.
Methods: Patients with operable stage II or III esophageal carci-
noma were staged by endoscopic ultrasonography and computed 
tomography. Two cycles of docetaxel (80 mg/m2) and carboplatin 
(target area under the concentration-time curve: 6 mg/ml × min) were 
delivered over 6 weeks. This was followed by concurrent weekly 
docetaxel (15 mg/m2), thoracic radiotherapy (50.4 Gy in 28 frac-
tions), and increasing doses of capecitabine (500–3500 mg) given 
before each fraction of radiotherapy. After restaging, responding 
patients continued to esophagectomy within 4 to 8 weeks of complet-
ing chemoradiotherapy.
Results: Forty-four patients were enrolled, and 40 were assessable 
for the dose-ranging component of concurrent chemoradiotherapy. 
Endoscopic ultrasonography stages at enrollment were T3N1 (29 
patients), T3N0 (4 patients), T2N1 (6 patients), and T4N0 (one 
patient). The maximum tolerated dose of capecitabine was 3500 mg. 
Thirty-six patients had surgery; 83% had R0 resection, and 17% had 
pathological complete response. Median overall survival was 23.5 
months, with 34 and 27% alive at 3 and 5 years.
Conclusion: The recommended phase II dose of capecitabine is 
3500 mg when given concurrently with 50.4 Gy of thoracic radio-
therapy in 28 fractions and weekly docetaxel. This trimodality ther-
apy for operable locally advanced esophageal carcinoma was very 
well tolerated and remarkably active. This regimen holds promise 
for the treatment of esophageal carcinoma and warrants further 
investigation.
Key Words: Esophageal carcinoma, Trimodality therapy, 
Capecitabine, Chemoradiotherapy, Phase 2 dose-escalation study, 
Clinical trial.
(J Thorac Oncol. 2013;8: 487-494)
Esophageal cancer is predicted to afflict 16,980 individuals in 2011, causing 14,710 deaths in that year.1 The disease 
has a poor outcome, with a 16.8% 5-year survival rate, largely 
because most patients present with regional or distant spread 
of disease.2 Surgical resection is a mainstay of treatment for 
stage II–III disease, but locoregional and systemic recurrence 
is common. Consequently, a number of clinical studies have 
focused on identifying neoadjuvant therapies to prevent recur-
rence and improve survival.
Numerous studies have evaluated the role for neo-
adjuvant chemotherapy and/or radiotherapy in surgically 
resectable esophageal carcinoma.3–5 A recent meta-analysis 
of neoadjuvant therapy trials encompassing 4188 patients 
showed that the hazard ratio for all-cause mortality was 0.78 
for neoadjuvant chemoradiotherapy and 0.87 for neoadjuvant 
chemotherapy compared with surgery alone.6 As the use of 
neoadjuvant chemoradiotherapy gained attention, a series 
of retrospective analyses indicated that addition of an inten-
sive induction chemotherapy regimen before concomitant 
chemoradiotherapy and surgery further improves outcomes.7,8 
Numerous phase II trials evaluating the induction chemother-
apy have shown that such regimens can be well tolerated and 
highly active, but results have varied widely because of the 
variation in agents, schedules, and dosing.9–19 In the absence 
of an accepted optimal approach, one focus for current trials 
is to identify regimens that maximize the quality of life and 
have minimal toxicity while maintaining acceptable clinical 
response and overall survival (OS).
The pyrimidine analog 5-fluorouracil (5-FU) is one of 
the most often studied chemotherapeutic agents in esophageal 
cancer.20 This agent requires central venous access for delivery, 
which carries a risk of infection and being inconvenient for 
patients. Capecitabine is an orally bioavailable prodrug of 
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5’-deoxy-5-fluorouridine, which is converted to 5-FU in 
tumor cells because of high expression of the converting 
enzyme thymidine phosphorylase in human carcinomas.21 
Capecitabine has shown promise in phase I and phase II 
studies for the treatment of esophageal cancer.22–25 High tumor 
expression of thymidine phosphorylase and its association with 
capecitabine responsiveness suggests a potentially valuable 
role for this agent in the treatment esophageal cancer.26
Docetaxel and paclitaxel are taxane class agents that sta-
bilize microtubules and interfere with cell division. Both the 
agents have a broad spectrum of antitumor activity, and both 
have been studied in esophageal cancer.27–29 Taxane treatment 
increases the expression of thymidine phosphorylase in mouse 
models of breast and colorectal cancer.30,31 Therefore, treat-
ment regimens containing docetaxel and capecitabine may 
have high therapeutic value because of a synergistic effect 
between these two agents. Preliminary studies of capecitabine 
and docetaxel combination therapy showed that these agents 
are well tolerated and highly active, but the study was limited 
by a small sample size and limited follow-up.32 The goal of this 
trial was to integrate oral capecitabine into a trimodal thera-
peutic regimen including induction chemotherapy followed 
by combination chemoradiotherapy and surgical resection. 
Capecitabine dosing was titrated upward during chemora-
diotherapy, and patients were monitored for the primary out-
come of dose-limiting toxicity (DLT). Secondary outcomes 
were OS, relapse-free survival (RFS), the rate of pathological 
complete response (pCR), and the rate of complete surgical 
resection.
PATIENTS AND METHODS
Patient Selection
Previously untreated patients with locally advanced, sur-
gically resectable cancer of the esophagus or gastroesophageal 
(GE) junction, clinical stage II–III (T2-4N0M0, T1-4N1M0) 
with histologic or cytologic evidence of adenocarcinoma or 
squamous cell carcinoma confirmed by the Department of 
Pathology at Dartmouth-Hitchcock Medical Center were eli-
gible. Patients having gastric cancer with minor involvement 
of the GE junction or distal esophagus were not eligible, nor 
were patients with cancer of the cervical esophagus. Celiac 
lymph node metastases were considered regional lymph node 
involvement (N1). Patients were required to be older than 
18 years, with Karnofsky performance status greater than or 
equal to 70%, and with adequate organ function defined by 
leukocytes greater than or equal to 3000 per cubic millimeter, 
platelets greater than or equal to 100,000 per cubic millime-
ter, bilirubin less than or equal to the upper limit of normal, 
serum transaminase (aspartate transaminase or alanine amino-
transferase) less than or equal to five times the upper limit of 
normal, serum creatinine less than or equal to 1.5 mg/dl, or cre-
atinine clearance of 50 mg × min/dl. Patients were not permit-
ted to have previous chemotherapy, immunotherapy, or chest/
abdominal radiotherapy. Patients with any of the following 
were excluded: clinically apparent metastatic disease (brain, 
bone, pulmonary, or liver metastases, or positive cytology of 
the pleura, pericardium, or peritoneum), clinically evident 
metastatic disease of the cervical or supraclavicular lymph 
nodes, grade greater than or equal to 2 peripheral neuropathy, 
serum calcium greater than 12 mg/dl, recurrent laryngeal or 
phrenic nerve paralysis, tracheobronchial tree involvement, 
tracheoesophageal fistula, concurrent active malignancy other 
than nonmelanoma skin cancer or carcinoma in situ of the 
cervix, or uncontrolled intercurrent medical illness. The study 
was performed in accordance with the Committee for the 
Protection of Human Subjects at Dartmouth College and mon-
itored by the Data Monitoring Committee of the Norris Cotton 
Cancer Center at Geisel School of Medicine at Dartmouth. 
All patients signed a Committee for the Protection of Human 
Subjects–approved informed consent before enrollment.
Clinical Staging
Initial evaluation included computed tomography (CT) 
scans of the chest and upper abdomen, upper gastrointestinal 
endoscopy with endoscopic ultrasonography (EUS), labora-
tory tests, and radiation therapy simulation all completed 
within 4 weeks of enrollment. A bone scan was performed 
in patients with abnormal alkaline phosphatase levels in the 
setting of normal aspartate transaminase, or patients with 
new-onset bone pain. A screening magnetic resonance imag-
ing or CT scan of the brain was performed for a recent his-
tory of headache or new focal neurologic findings. EUS was 
performed with an Olympus gastroscope (Olympus America, 
Center Valley, PA) under conscious sedation in the usual man-
ner. At the time of initial clinical staging, biopsies were taken 
for evaluation by the Department of Pathology, Dartmouth-
Hitchcock Medical Center. Before surgical resection, patients 
were restaged by repeat CT scans of the chest and upper abdo-
men and upper gastrointestinal endoscopy with EUS.
Treatment Plan
In the induction phase, patients were treated with two 
cycles of docetaxel (80 mg/m2) and carboplatin (target area 
under the concentration-time curve: 6 mg/ml × min) every 
21 days for 6 weeks. In the concurrent chemoradiotheraputic 
(CCRT) phase, all patients received weekly docetaxel (15 mg/
m2) and external beam radiotherapy (50.4 Gy at 1.8 Gy per 
fraction in 28 fractions, delivered Monday through Friday). 
The patients underwent CT simulation in an immobilized 
state, with arms up using a wing-board and vac-bag. All 
patients underwent three-dimensional treatment planning. The 
dose was calculated using tissue heterogeneity corrections. 
The planned treatment volume 1 (PTV1) included the gross 
tumor volume with a 4- to 5-cm proximal and distal margins 
and 1.5 to 2 cm circumferential margins. The celiac nodes 
were electively covered in distal and GE junction carcinomas. 
The planned treatment volume 2 (PTV2) was designed with a 
1.5- to 2-cm margin around the gross tumor volume. Margins 
around the grossly positive nodes were kept at 1 to 1.5 cm in 
both PTV1 and PTV2. PTV1 received 41.4 Gy in 23 fractions. 
A boost of 9 Gy in five fractions was delivered to PTV2. The 
constraints for the organs at risk were kept under tolerance: 
less than 32% of the lung volumes received more than 20 Gy, 
less than 50% of the heart volume received more than 40 Gy, 
and the maximum dose to any point on the spinal cord was 
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kept less than 45 Gy. Before each fraction of radiotherapy, 
patients took a set dose of oral capecitabine ranging from 
500 mg at dose level I to 3500 mg at dose level VII, in 500-
mg increments. DLT was defined as any grade 3 or higher 
toxicity, which did not return to grade 2 or lower within 3 
weeks from the completion of treatment, or any grade toxicity 
that resulted in a treatment break longer than 1 week. Initially, 
three patients were enrolled at dose level I. If one or more 
patients developed DLT, three more patients were enrolled 
at the same dose level. If there was no DLT, the next three 
patients were enrolled at the next incremental dose level. The 
maximum tolerated dose (MTD) was defined as the dose of 
capecitabine at which 33% of patients experience a DLT. This 
experimental design follows the approach outlined by Storer 
for DLT studies.33
Efficacy Analysis
The primary outcome for this study is the occurrence 
of DLT during the escalation phase of concomitant chemo-
radiotherapy treatment. Secondary outcomes include changes 
in patient weight and performance status after chemoradio-
therapy, frequency of minor toxicity, OS, RFS, disease-spe-
cific survival, curative surgical resection rate, and pCR rate. 
All survival outcomes were determined from the date of study 
enrollment. RFS was measured to the date of documented 
disease progression, incomplete surgical resection, or death 
from any cause. OS was measured to the date of death from 
any cause, regardless of the disease status. Disease-specific 
survival was measured to the date of death from esophageal 
cancer or complications of surgery, with other causes of death 
censored at the time of death. Patients who were living or lost 
to follow-up without progressive disease were censored at the 
date of the last documented clinical encounter. Surgical out-
comes were defined as (1) R0: curative resection, all gross 
disease removed, surgical margins free of tumor; (2) R1: pal-
liative resection, gross tumor left behind, or positive surgi-
cal margins on pathology; or (3) R2: no resection, primary 
tumor could not be removed. Positive radial margins were 
considered R1 resection. pCR was defined as the absence of 
residual carcinoma at the primary site on microscopic exami-
nation. Microscopic residual disease (MRD) was defined as 
the presence of only single cancer cells or small groups of 
cancer cells in the background of fibrosis, according to the 
reporting pathologist. Significant residual disease was defined 
as multiple residual cancer cells in the background of fibrosis 
or as residual carcinoma without evidence of treatment effect. 
All cases that were downstaged to ypT0 or ypT1 had slides 
reviewed by a pathologist for pCR or MRD, regardless of the 
nodal or distant disease. Surgical mortality was defined as 
death within 30 days of the surgical procedure.
RESULTS
Patient Characteristics
Forty-four patients were enrolled. Four patients were 
replaced during the induction phase – two because of the 
discovery of metastatic disease during staging, one because 
of withdrawal of consent before treatment, and one because 
of death from a nonneoplastic cause (cerebrovascular acci-
dent). Demographical and clinical characteristics of the 40 
patients who initiated induction are summarized in Table 1. 
Patients had a median age of 63 years (range, 47–87 years), 32 
patients (80%) were men, and 36 patients (90%) had adeno-
carcinoma. Clinical stages at enrollment were T3N1 (n = 29, 
72.5%), T2N1 (n = 6, 15%), T3N0 (n = 4, 10%), and T4N0 (n 
= 1, 2.5%) with disease involving the distal esophagus (n = 
12, 30%), the distal esophagus and the GE junction (n = 19, 
47.5%), or both these areas and the cardia of the stomach (n = 
8, 20%). One patient (2.5%) had disease of the midesophagus. 
The accrual and treatment course of the cohort is shown in 
Figure 1. During the CCRT phase, one patient died from acute 
respiratory distress syndrome, whereas two patients withdrew 
consent for low-grade toxicity. Both of these patients later 
continued to surgery: one had surgical resection, whereas the 
other was found to have liver metastases, so no resection was 
performed. Of 37 patients who completed CCRT, one declined 
surgery and one transitioned to hospice care, whereas the 
remaining 35 patients proceeded to surgery. The total number 
of patients having resection was therefore 36 (90% of those 
who received induction), one of whom did not complete the 
full course of CCRT. Thirty-three of 36 patients survived the 
surgical and postoperative period, for a surgical mortality rate 
of 8.3%. One patient was found to have stage IV disease at the 
time of surgery.
TABLE 1.  Patient Characteristics
 Number Percent (%)
Patients 40
Age (years)
 Median 63
 Range 47–87
Sex
 Male 32 80
 Female 8 20
Performance status
 90% 29 72.5
 80% 8 20
 70% 3 7.5
Sites of disease
 Distal esophagus (DE) 12 30
 DE and GE junction 19 47.5
 DE, GE junction, and cardia 8 20
 Midesophagus 1 2.5
Histology
 Adenocarcinoma 36 90
 Squamous cell carcinoma 4 10
Clinical stage
 T4N0 1 2.5
 T3N1 29 72.5
 T3N0 4 10
 T2N1 6 15
GE, gastroesophageal junction.
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Safety Parameters
There were seven DLTs in CCRT phase, occurring across 
five different doses of capecitabine (Table 2). Two patients 
had grade 3 dysphagia (at 500 and 1500 mg capecitabine), 
one patient had thrombocytopenia (at 1500 mg), one had 
grade 3 fatigue (at 3000 mg), and one had grade 3 pneumo-
nitis (at 3500 mg). Two patients at 3500 mg withdrew consent 
for toxicities – one for severe nausea and one for persistent 
neuropathy. Although these were objectively less than grade 
3 or 4 events, the patients were unable to tolerate these toxic 
effects and declined further participation in the study. Because 
of the clinical impact of these events and the associated pro-
longed treatment interruption, we considered them to be dose 
limiting. Therefore, from a total of nine patients treated at 
3500 mg, three patients (33.3%) had DLT, meeting the defini-
tion for maximally tolerated dose.
All grade 3 or 4 toxicities (including the dose-limiting 
toxicities) that occurred among patients receiving CCRT are 
enumerated in Table 3. The most common nonhematologic 
event was dysphagia, occurring in six patients (15%). The 
most common hematologic toxicity was absolute neutrophil 
content abnormality during induction, occurring in 10 patients 
(25%). More than half of the participants had no events of 
grade 3 or higher (n = 23, 58%), and several categories of 
adverse event never occurred with severity above grade 2.
Efficacy Parameters
The median follow-up time was 18.5 months. OS and 
RFS were computed from 40 patients who started induction 
therapy, measured from the time of enrollment (Fig. 2). The 
median OS was 23.5 months, with 62, 34, and 27% of patients 
alive at 1, 3, and 5 years of follow-up. The median RFS was 
15.6 months, with 63% of patients free from relapse at 1 year. 
The 3- and 5-year RFSs were both 37%. The median disease-
specific survival was 28.1 months (Fig. 3A).
Thirty-six patients had surgical resection, with the vast 
majority (30 of 36, 83%) having R0 resection. One of the 
patients with R0 resection of the primary tumor was found to 
have a single nodule of metastatic disease embedded in the 
abdominal wall, which was completely resected. Five patients 
had R1 resection, with tumor microscopically present at the 
proximal, distal, or radial margins. Two of these patients 
had positive radial margins, and two others had isolated 
tumor cells in lymphovascular spaces. Only one patient had 
microscopic extension of the primary tumor to a proximal or 
distal margin. One patient had gross residual disease involving 
the chest wall and was classified as R2. Six patients (16.7%; 
95% confidence interval [CI]: 4.5–28.8%) had a pCR at the 
primary site, and an additional five patients had microscopic 
foci of residual tumor cells at the primary site. Based on 
evidence that MRD and pCR have identical outcomes with 
respect to OS, we considered these two groups together.34 We 
found that 11 patients (30.6%; 95% CI: 15.5–45.6%) who 
FIGURE 1.  Accrual and treatment course. 
Patients accrued and treated throughout 
the trial are shown. CRT, chemoradiother-
apy; MRD, microscopic residual disease; 
pCR, pathological complete response.
TABLE 2.  Dose-Limiting Toxicity by Level
Level Capecitabine (mg) n DLT % DLT
I 500 7 One grade 3 dysphagia 14.3
II 1000 3 None 0
III 1500 6 One grade 3 dysphagia 16.7
IV 2000 3 None 0
V 2500 6 One thrombocytopenia 16.7
VI 3000 6 One grade 3 fatigue 16.7
VII 3500 9 One grade 3 pneumonitis 33.3
One withdrawal for nausea
One withdrawal for neuropathy
DLT, dose-limiting toxicity.
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had pCR or MRD had a median survival of 86.6 months, 
compared with a median survival of 19.1 months for 25 
patients who had a greater extend of residual disease. The 
pCR/MRD group had a 61.4% survival rate at both 3 and 5 
years, compared with 27.5% at 3 years and 18.4% at 5 years 
for patients with significant residual disease (Fig. 3B). This 
result was statistically significant by the log-rank test, with a 
p value of 0.026.
Nineteen of 37 patients (51%) who completed CCRT 
had a stable or improved Karnofsky performance status, 
whereas 13 patients (35%) dropped by 10%, and five patients 
(14%) dropped by 20%. No patient dropped their perfor-
mance status to less than 70%. The average weight loss 
among CCRT patients was 4.6 kg. Six patients (15%) required 
a feeding tube before surgery, and in three of these patients, 
the feeding tube was required because of the tumor causing 
obstruction of the esophagus rather than toxicity from the 
chemoradiotherapy.
DISCUSSION
Esophageal cancer presents a therapeutic challenge 
because of the advanced stage of disease at clinical 
presentation and frequent local recurrence. One approach to 
therapy consists of an intensive chemotherapeutic regimen, 
followed by lower doses of chemotherapy combined with 
radiotherapy. This approach may improve local disease control, 
achieve downstaging for easier surgical resection, and treat 
occult metastatic disease. Such regimens, however, can carry 
significant toxicity. Capecitabine and docetaxel are promising 
agents for such trimodal therapy, because of potential synergistic 
effects, reduced toxicity, and easy delivery. We investigated 
a trimodal regimen including phase 2 dose escalation of 
TABLE 3.  Grade 3 or 4 Toxicity Events by Dose Level
 Level I Level 
II
Level 
III
Level 
IV
Level 
V
Level 
VI
Level 
VII
Total(n = 7) (n = 3) (n = 6) (n = 3) (n = 6) (n = 6) (n = 9)
Cardiac 0 0 0 0 0 1 0 1
Pulmonary 0 0 1 0 0 0 0 1
Dehydration 0 0 0 0 0 0 1 1
Dysphagia 1 0 1 1 0 3 0 6
Odynophagia 0 0 0 0 0 1 0 1
Weight loss 0 0 0 1 0 0 0 1
Nausea/ 
vomiting
0 0 1 0 0 1 1 3
Fatigue 0 0 0 0 0 1 0 1
Preradiation 
therapy
 WBC 4 2 2 0 0 1 0 9
 ANC 5 3 2 0 0 0 0 10
 Platelets 0 0 0 0 0 0 0 0
 Hgb 0 0 0 0 0 0 0 0
During radiation 
therapy
 WBC 1 0 0 0 0 0 0 1
 ANC 0 0 0 0 0 0 0 0
 Platelets 0 0 0 0 0 2 0 2
 Hgb 0 0 0 0 0 1 1 2
Neutropenic 
fever
0 0 0 0 0 1 0 1
Laboratory 
abnormalities
1 1 0 0 0 4 1 7
Total grade 3–4 
events
12 6 7 2 0 16 4 47
Number (%) 
with any grade 
3–4 event
5 
(71)
3  
(100)
3  
(50)
1  
(33)
0  
(0)
4 
(67)
1  
(11)
17 
(42.7)
The following events did not occur above grade 2: diarrhea, constipation, shortness 
of breath, cough, headache, myalgia/arthralgia, insomnia, alopecia, rash, dermatologic, 
epitasis, visual disturbances, and taste disturbances.
ANC, absolute neutrophil count; Hgb, hemoglobin; WBC, white blood cell.
FIGURE 2.  Overall and relapse-free survival. Kaplan–Meier 
curves are shown for overall survival (A) and relapse-free sur-
vival (B) among 40 patients who initiated induction therapy. 
Values for median overall survival and absolute survival at 1, 
3, and 5 years are indicated on each chart.
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capecitabine in patients with resectable esophageal cancer and 
found that this regimen produced excellent median and 5-year 
survival, with a low burden of toxicity.
Several recent phase 2 studies have evaluated trimodal 
therapies in esophageal carcinoma, including both adenoma-
tous and squamous histology, with a high-intensity induction 
chemotherapy phase before concomitant chemoradiotherapy 
(Table 4). The rates of R0 resections have ranged from 76 to 
100%. By comparison, our study achieved a reasonable rate 
of 83% R0 resection. In four of five R1 resections, disease 
extended to the radial margins or to the lyphovascular space, 
whereas only one case had a microscopically positive mar-
gin at the proximal or distal aspect. Therefore, even in cases 
that were strictly defined as R1, the degree of marginal dis-
ease was minimal, suggesting a potent therapeutic effect. In 
the same set of studies, pCR rates among patients who had 
resection ranged from 20 to 40%, whereas our study achieved 
a pCR rate of 17% and pCR/MRD rate of 30.6%. This may 
be a result of the sample size, and in fact, the 95% CI for 
our response rate overlaps with many of the response rates 
in previous studies. This may reflect the range of efficacy 
for this trimodal regimen; it must be noted that our surgi-
cal outcomes are confounded by the dose-escalation aspect 
of the chemoradiotherapy phase. It is possible that using the 
MTD of capecitabine (3500 mg) would produce better and 
less variable results. Furthermore, recent reports have found 
that tumor histology can influence the treatment response. 
Specifically, patients with squamous cell carcinoma are more 
likely to achieve a pCR, but they are also more prone to distal 
recurrence.35 Therefore, one factor potentially explaining our 
lower than expected pCR rate may be a higher frequency of 
adenocarcinoma compared with most other studies (Table 4). 
In this cohort, 34 patients (85%) had T3 or higher staging at 
enrollment, which is comparable to other studies. Compared 
with a landmark clinical trial of 5-FU and cisplatin, this regi-
men produced a superior median OS (23.5 versus 18 months) 
and 3-year survival (34 compared with 25%).36
As expected, we observed that patients having either 
pCR or MRD had a better 5-year survival compared with 
patients with a greater burden of residual disease. Although 
there is evidence that these two categories can be considered 
together, Verlato et al. recently reported that the prognos-
tic value of absent or scattered residual cancer cells varies 
depending on node status.37 Considering that the main goal of 
this work is to define MTD of capecitabine, and consequently 
we have a small number of patients in the cohort, we do not 
believe it is appropriate to draw any firm conclusions on the 
prognostic value of pCR versus MRD in our population.
One advantage of this regimen is the overall tolerabil-
ity. Grade 3 or 4 toxicity occurred in a minority of patients 
and was largely limited to dysphagia, nausea/vomiting, and 
laboratory abnormalities. Few patients required a feed-
ing tube before surgery, indicating that induction therapy 
helped to preserve swallowing function, which enabled 
delivery of oral capecitabine. These results are consistent 
with data from a smaller set of patients who were treated 
with a capecitabine-/docetaxel-based regimen.32 One limita-
tion of our study is that at the highest tolerated dose level of 
capecitabine (3500 mg), two of the patients had objectively 
low-grade toxicities that resulted in withdrawal from the 
study. It is possible that higher doses of capecitabine might 
be tolerated without producing grade 3 or higher toxicities, 
but our study was limited by our definition of DLT to include 
prolonged treatment breaks. We concluded that 3500-mg 
capecitabine was the highest practically achievable dose and 
an appropriate end point for a MTD study.
FIGURE 3.  Disease-specific and subgroup survival. (A) 
Disease-specific survival was calculated among enrolled 
patients. (B) Kaplan–Meier curves for overall survival among 
36 patients who had surgical resection are shown for patients 
having pathological complete response or microscopic 
residual disease (n = 11) versus those having a higher level of 
residual disease (n = 25). The p value represents a log-rank 
test.
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In conclusion, a trimodal approach including 
capecitabine and docetaxel was well tolerated and produced 
acceptable OS rates, although the pathological response rate 
was low compared with other studies. The low pCR rate was a 
surprising result, but we believe the high tolerability and favor-
able survival outcomes make a strong case for further studies 
with the MTD of capecitabine, where better pCR rates might 
be attained. Despite the low pCR rate, OS was comparable to 
other studies, and this is a more direct outcome. We identi-
fied 3500 mg as the MTD of capecitabine in this regimen. We 
suggest that survival and response might be further improved 
by treating with the maximum tolerated capecitabine dose. 
High-grade toxicity was uncommon. This method of treat-
ment warrants further investigation and has the potential to 
prolong survival and increase quality of life among patients 
with resectable esophageal carcinoma.
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TABLE 4.  Outcomes of Phase 2 Studies with Trimodal Therapy
Author (year) Induction CCRTa Resected/total
Of resected Of total
% R0 % pCR % Adenocarcinoma % ≥T3
Ajani (2001)13 5-FU 45 Gy 25/38 100 30 82 87
Cisplatin 5-FU
Paclitaxel Cisplatin
Bains (2002)9 Cisplatin 50.4 Gy 36/41 92 22 61 83
Paclitaxel Cisplatin
Paclitaxel
Swisher (2003)17 5-FU 45 Gy 35/38 100 23 84 87
Cisplatin 5-FU
Paclitaxel Cisplatin
Ajani (2004)14 Irinotecan 45 Gy 39/43 100 28 86 85
Cisplatin 5-FU
Paxlitaxel
Henry (2006)16 Cisplatin 45 Gy 16/21 100 25 86 NR
Paclitaxel 5-FU
Cisplatin
Paclitaxel
Ruhstaller (2009)11 Cisplatin 45 Gy 57/66 93 26 55 82
Docetaxel Cisplatin
Docetaxel
Ajani (2010)15 Docetaxel 50.4 Gy 43/55 76 20 98 96
Irinotecan Docetaxel
5-FU Irinotecan
5-FU
Choong (2010)18 Docetaxel 50 or 66 Gy 45/78 93 40 77 NR
Cisplatin Docetaxel
Eisterer (2011)19 Cisplatin 40 or 60 Gy 16/24 100 31 33 75
Docetaxel Docetaxel
5-FU 5-FU
De Vita (2011)10 FOLFOX-4 50.4 Gy 30/41 80 27 32 NR
Cetuximab Cetuximab
Ruhstaller (2011)12 Cisplatin 45 Gy 25/28 100 36 54 64
Docetaxel Cisplatin
Cetuximab Cetuximab ± docetaxel
Wood (current study) Docetaxel 50.4 Gy 36/40 83 17 90 85
Carboplatin Capecitabine
Docetaxel
aConcomitant chemoradiotherapy.
5-FU, 5-fluorouracil; CCRT, concurrent chemoradiotheraputic phase; NR, not reported; pCR, pathological complete response.
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